Last updated: August 6, 2026
Cosmo Technologies Limited sued Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after Mylan filed an ANDA seeking approval to market generic budesonide extended-release tablets, the generic counterpart to Cosmo’s UCERIS product. The case was a Hatch-Waxman patent action centered on U.S. Patent No. 8,865,688. The docket ended without a reported trial judgment or publicly reported invalidity decision against Mylan. The parties resolved the dispute through a settlement-related dismissal, and the material commercial terms were not publicly disclosed. [1]
What product and patent were involved in Cosmo v. Mylan?
The dispute concerned UCERIS, a 9 mg delayed-release budesonide tablet approved for the induction of remission in patients with active, mild-to-moderate ulcerative colitis.
| Item |
Detail |
| Branded product |
UCERIS |
| Active ingredient |
Budesonide |
| Dosage form |
9 mg delayed-release oral tablet |
| NDA holder |
Salix Pharmaceuticals, Ltd., with Cosmo-related ownership and commercialization rights |
| FDA NDA |
NDA 203634 |
| Generic applicant |
Mylan Pharmaceuticals Inc. |
| ANDA |
ANDA No. 207635 |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:16-cv-00152 |
| Filing date |
February 19, 2016 |
| Principal patent |
U.S. Patent No. 8,865,688 |
| Statutory basis |
35 U.S.C. § 271(e)(2), Hatch-Waxman infringement |
Cosmo’s patent estate covered the controlled delivery of budesonide to the colon through a multiparticulate or matrix-based oral formulation. UCERIS uses MMX, or Multi-Matrix System, delivery technology intended to delay release until the dosage form reaches the colon. FDA product labeling identifies UCERIS as a budesonide extended-release tablet. [2]
What patent protected UCERIS in the Mylan litigation?
U.S. Patent No. 8,865,688 was the principal patent asserted against Mylan in the case. The patent was assigned to Cosmo Technologies Limited and related Cosmo entities and concerned pharmaceutical compositions and delivery systems for releasing active ingredients in the colon.
The asserted patent was significant because it addressed the formulation platform rather than budesonide as a chemical compound. Budesonide itself was an established corticosteroid with no meaningful compound-patent barrier remaining by the time UCERIS was commercialized. The commercial protection therefore depended on formulation, delivery, and method-of-use rights.
Patent profile
| Patent |
Subject matter |
Role in litigation |
Reported expiration |
| U.S. 8,865,688 |
Colon-targeted budesonide formulation and delivery technology |
Principal patent asserted against Mylan |
Approximately 2029, subject to patent-term adjustment and regulatory exclusivity calculations |
Public patent databases and FDA Orange Book records should be read together when evaluating the effective protection period. The patent expiration date does not by itself establish the earliest lawful generic launch date because settlement terms, pediatric exclusivity, later-listed patents, and regulatory approval timing can affect market entry. [3][4]
When did Cosmo sue Mylan, and what triggered the case?
Cosmo filed the action on February 19, 2016, after Mylan submitted an ANDA containing a Paragraph IV certification concerning the patent listed for UCERIS.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing the certification and notifying the patent owner creates the statutory basis for a patent action under 35 U.S.C. § 271(e)(2).
The filing of the lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval, assuming the statutory requirements were satisfied. The stay prevents FDA approval of the ANDA during the statutory period unless the court resolves the case earlier or the stay is otherwise terminated. [5]
What were the principal legal issues?
The litigation presented the standard issues associated with a Paragraph IV formulation challenge.
Infringement
Cosmo would have argued that Mylan’s proposed budesonide extended-release tablets met the limitations of the ’688 patent. The relevant questions likely included:
- Whether Mylan’s formulation used the claimed delivery architecture.
- Whether the dosage form released budesonide in the claimed gastrointestinal region.
- Whether the formulation satisfied the patent’s matrix, coating, excipient, or release-profile limitations.
- Whether the ANDA product would infringe literally or under the doctrine of equivalents.
Because ANDA litigation evaluates the proposed product described in the ANDA, the court would not need to wait for commercial launch to determine infringement.
Invalidity
Mylan’s principal defenses would have included obviousness, anticipation, written description, enablement, and indefiniteness. The most commercially relevant defense for a formulation patent was likely obviousness based on prior budesonide formulations, enteric-release systems, colonic delivery technologies, and known excipient combinations.
Formulation patents often face a narrower validity inquiry than compound patents. The patent holder must show that the claimed delivery profile or combination produced a non-obvious result, not merely that the product was useful.
Enforceability
The docket does not show a publicly reported finding that the ’688 patent was unenforceable. No reported decision in this action established inequitable conduct, prosecution laches, or another enforceability defense against Cosmo.
What was the outcome of Cosmo Technologies v. Mylan?
The case ended through a settlement-related dismissal rather than a reported trial decision.
The public docket does not disclose the complete settlement terms. The available record does not establish:
- Mylan’s agreed launch date.
- Whether Mylan received an authorized-generic supply right.
- Whether Mylan agreed to a license.
- Whether the settlement included a no-AG provision.
- The royalty or other economic terms.
- Whether the settlement required Mylan to concede patent validity or infringement.
The dismissal therefore does not establish that the ’688 patent was valid, infringed, or enforceable against Mylan. It establishes that the parties terminated the litigation without a public merits judgment. [1]
Did Mylan launch a generic UCERIS product?
The case docket alone does not establish a commercial launch date for Mylan’s generic budesonide extended-release tablets.
A generic applicant can resolve patent litigation through a settlement that permits launch before patent expiration. The date may be confidential or may appear indirectly in later FDA, company, or market records. FDA approval and commercial launch are separate events: approval authorizes marketing, while launch reflects the applicant’s commercial decision and the settlement’s operative restrictions.
The Mylan litigation should therefore be treated as a resolved patent dispute, not as evidence of a specific generic launch date.
What was the Orange Book status of UCERIS?
UCERIS was listed in the FDA Orange Book with patent information associated with the formulation and delivery technology. The Orange Book listing gave the patent holder a statutory basis to challenge an ANDA applicant filing a Paragraph IV certification.
The relevant distinction is between:
- Orange Book-listed patents, which can trigger Hatch-Waxman litigation and the 30-month stay; and
- Other patents, including process, manufacturing, or later-developed method-of-use patents, which may not create the same statutory approval barrier.
The ’688 patent was the core Orange Book-linked protection relevant to the Mylan action. Later UCERIS-related patents may affect current launch analysis, but they do not change the procedural history of the 2016 case. [3]
How strong was Cosmo’s patent estate?
Cosmo’s estate was stronger in formulation and delivery technology than in active-ingredient exclusivity.
Strengths
- The patents targeted a commercially important delivery system.
- The formulation was tied to a specific oral dosage form.
- The patents created a basis for Paragraph IV litigation.
- The technology could be difficult to design around without changing release characteristics or product performance.
- The estate supported protection after budesonide’s compound exclusivity had expired.
Weaknesses
- Formulation claims are vulnerable to obviousness challenges based on combinations of known excipients and release technologies.
- The technical scope may depend on precise claim construction.
- A generic applicant can attempt a non-infringing formulation with a different coating, matrix, particle structure, or dissolution profile.
- FDA approval of a different dosage-form architecture can weaken practical exclusivity even when the original patent remains in force.
- Patent expiry was materially closer than it would have been for a new chemical entity protected by a compound patent.
The settlement prevented a public assessment of the ’688 patent’s validity and infringement strength against Mylan. The absence of a merits decision is commercially important: it leaves the patent’s litigation risk unresolved rather than confirmed.
What patent litigation affected UCERIS besides the Mylan case?
Cosmo and related entities pursued other Hatch-Waxman cases involving generic versions of UCERIS. The litigation landscape included actions against other generic applicants, including Actavis and Dr. Reddy’s Laboratories.
Those cases were relevant because they addressed the same or related UCERIS formulation patents and could have produced claim-construction or validity rulings affecting multiple ANDA defendants. A judgment in one coordinated or technically similar case could materially change settlement leverage in another.
The Mylan action itself, however, did not produce a reported final merits opinion. Its outcome must be analyzed separately from any Federal Circuit or district court rulings in related UCERIS cases.
What did the settlement mean for generic entry risk?
The settlement removed Mylan as an active litigant but did not eliminate the broader generic-entry risk to UCERIS.
Near-term effect
The settlement likely preserved Cosmo’s ability to control Mylan’s market entry under confidential terms. If Mylan received a negotiated launch date, the settlement converted litigation uncertainty into a defined commercial timetable for the parties.
Long-term effect
Generic entry risk remained tied to:
- The expiration of the ’688 patent.
- Any later-listed formulation or method-of-use patents.
- The enforceability of settlement restrictions.
- FDA approval timing.
- The ability of other ANDA applicants to challenge the same patents.
- The availability of alternative budesonide formulations.
A settlement with one applicant does not bind unrelated generic applicants unless the relevant patents, contractual arrangements, or court orders create broader effects.
How does UCERIS patent protection compare with compound-based drugs?
UCERIS relied primarily on formulation and delivery protection. A compound-based product normally has a stronger exclusionary position because competitors must identify a different active ingredient or wait for compound-patent expiry.
| Protection type |
UCERIS position |
Commercial consequence |
| Compound patent |
Limited or expired for established budesonide |
Low barrier to alternative budesonide products |
| Formulation patent |
Central to the ’688 patent |
Main basis for ANDA litigation |
| Method-of-use patent |
Potential supplemental protection |
May be difficult to enforce against skinny-label products |
| Manufacturing patent |
Possible process barrier |
Usually less effective if generic can use a different process |
| Regulatory exclusivity |
Ended before the 2016 case |
Patent litigation, not exclusivity, controlled the dispute |
For investors and licensing parties, the key risk is substitution. If a competitor can develop a bioequivalent budesonide product using a different formulation that avoids the patent claims, the formulation estate may not block all market competition.
What is the current legal significance of 1:16-cv-00152?
The case is primarily relevant as evidence of Cosmo’s enforcement strategy for UCERIS and the commercial value of the ’688 formulation patent.
It demonstrates that:
- Mylan pursued a Paragraph IV route rather than waiting passively for patent expiry.
- Cosmo enforced the Orange Book-listed formulation patent.
- The parties resolved the dispute without a public validity or infringement ruling.
- The settlement preserved uncertainty concerning the patent’s ultimate litigation strength.
- Generic entry analysis requires review of the settlement, Orange Book records, later patents, and FDA approval data rather than the dismissal alone.
Key Takeaways
- Cosmo sued Mylan in Delaware on February 19, 2016, in Civil Action No. 1:16-cv-00152.
- The case concerned Mylan’s ANDA for generic budesonide delayed-release tablets corresponding to UCERIS.
- U.S. Patent No. 8,865,688 was the principal patent at issue.
- The case was triggered by Mylan’s Paragraph IV certification.
- The litigation ended by settlement-related dismissal without a reported merits judgment.
- Public records do not establish the settlement’s launch date, economic terms, or authorized-generic provisions.
- Cosmo’s protection depended on formulation and colon-targeted delivery patents rather than a durable budesonide compound patent.
- The case reduced Mylan-specific litigation uncertainty but did not remove broader generic-entry risk.
FAQs About Cosmo Technologies v. Mylan
What drug was involved in Cosmo Technologies Limited v. Mylan?
The case involved generic budesonide delayed-release tablets corresponding to UCERIS, a 9 mg oral treatment for ulcerative colitis.
Was U.S. Patent No. 8,865,688 invalidated in the Mylan case?
No reported decision in the Mylan action invalidated the patent. The case ended without a public trial judgment.
Did Mylan win the Cosmo UCERIS patent lawsuit?
The public docket does not show a merits victory for Mylan. The parties resolved the action through a settlement-related dismissal.
Did the Cosmo-Mylan settlement authorize an early generic launch?
The public record does not disclose the settlement’s launch provisions. The dismissal alone does not establish an early-entry date.
Can another generic company challenge the UCERIS patents after Mylan settled?
Yes. A settlement with Mylan does not prevent an unrelated ANDA applicant from filing its own Paragraph IV challenge, subject to the status of the listed patents and any applicable regulatory exclusivity.
References
- U.S. District Court for the District of Delaware. (2016). Cosmo Technologies Limited v. Mylan Pharmaceuticals Inc., No. 1:16-cv-00152-LPS, docket record.
- U.S. Food and Drug Administration. (2012). UCERIS (budesonide) extended-release tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book, UCERIS listing.
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,865,688, pharmaceutical compositions for the treatment of inflammatory bowel disease.
- 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
